Holly Douglas
Holly’s career as an analytical chemist has spanned jobs at Novartis, GSK and the Francis Crick Institute, covering a range of environments from drug discovery to final product testing to metabolomics. Since joining AstraZeneca four years ago, Holly’s focus has been on improving analytical workflows and data quality using both software and hardware automation and integrating these analytical workflows into the Global AstraZeneca scientific ecosystem to enable acceleration of the DMTA cycle.